{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-218037","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.336757+00:00","generated_at":"2026-06-11T05:21:23.780080+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaccinex raises ~$650K in private placement of 3.14M shares at $0.207/share","bullets":["Issued 3,140,095 shares to accredited investors at $0.207 per share for gross proceeds of approximately $650,000.","Shares sold in unregistered transaction under Section 4(a)(2) and Rule 506 of Regulation D.","Company to use net proceeds for pepinemab development, working capital, and general corporate purposes.","Registration rights agreement requires company to file resale registration statement within 120 days of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-218037","json":"https://secwatch.observer/filing/0001193125-23-218037.json","markdown":"https://secwatch.observer/filing/0001193125-23-218037.md","text":"https://secwatch.observer/filing/0001193125-23-218037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523218037/0001193125-23-218037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523218037/d510574d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:21:23.780080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb0b56f8810af5641ca40a12c480d390f3375539","claim":"VACCINEX, INC. entered into Stock Purchase Agreement with the investors named therein valued at aggregate gross proceeds of approximately $650,000 (effective 2023-08-18).","evidence_excerpt":"On August 18, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the investors named therein (the “Investors”) an aggregate of 3,140,095 shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), at a purchase price of $0.207 per Share (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523218037/0001193125-23-218037-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors named therein"},{"label":"Value","value":"aggregate gross proceeds of approximately $650,000"},{"label":"Effective","value":"2023-08-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}